Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift - Takeaways - MDSpire

Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift

  • By

  • Yali Li

  • Shiying Li

  • Yuning Zhang

  • Yuhan Chen

  • Tao Guo

  • Chen Li

  • June 9, 2026

  • 0 min

Share

  • 1

    Acrodermatitis continua of Hallopeau (ACH) is a chronic pustular psoriasis affecting distal fingers and toes, often resistant to conventional treatments.

  • 2

    Systemic IL-17 inhibitors can cause immune drift, leading to eczematous eruptions, complicating treatment for ACH.

  • 3

    A 13-year-old female with refractory ACH improved significantly after receiving local injections of diluted Xeligekimab.

  • 4

    After 16 weeks, the patient's PPPASI, DLQI, and NAPSI scores showed substantial improvement, with no recurrence of eczema.

  • 5

    Local administration of IL-17 inhibitors may effectively manage ACH while avoiding systemic immune imbalance, warranting further research.

Original Source(s)

Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift

  • by Yali Li, Shiying Li, Yuning Zhang, Yuhan Chen, Tao Guo, Chen Li

  • June 9, 2026

Related Content

Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Correction: Association between Life's Essential 8 and psoriasis in US adults: a cross-sectional study